Skip to content
In primary membranous nephropathy, obinutuzumab increased the likelihood of complete remission vs. tacrolimus at 104 wk
All contributors

Onconephrology contributor

Palladini, Giovanni

Primarily MGRS & paraprotein kidney disease#21 of 46 recognizedHonor roll
33
Clinical papers
3,036
Citations (iCite)
10 / 8
First / senior author
2005–2026
Active years

Output over time

Clinical corpus papers per year — peak 5 in 2018, 2020.

  • 2005: 1 paper
  • 2007: 1 paper
  • 2013: 2 papers
  • 2014: 2 papers
  • 2015: 1 paper
  • 2016: 1 paper
  • 2017: 2 papers
  • 2018: 5 papers
  • 2020: 5 papers
  • 2021: 2 papers
  • 2022: 4 papers
  • 2023: 2 papers
  • 2024: 2 papers
  • 2025: 2 papers
  • 2026: 1 paper
20052026

Subfield mix

Clinical papers by onconephrology subfield (a paper can count in more than one).

MGRS & paraprotein kidney disease33
Myeloma cast nephropathy10

Frequent co-authors

Other recognized contributors who most often share corpus papers with Palladini (shared-paper count).

Merlini, Giampaolo25Wechalekar, Ashutosh D7Kastritis, Efstathios5Dispenzieri, Angela3Gertz, Morie A3Leung, Nelson2

Verify

Representative recent papers, and this author’s full PubMed bibliography.

PMID 42118698 (opens PubMed in a new tab)PMID 40534508 (opens PubMed in a new tab)PMID 39931632 (opens PubMed in a new tab)PMID 39088206 (opens PubMed in a new tab)PMID 38824453 (opens PubMed in a new tab)PMID 37516426 (opens PubMed in a new tab)All papers on PubMed

A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,541-article corpus (regenerated 2026-10-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.